The Norwegian Radium Hospital

What The Norwegian Radium Hospital does

The Norwegian Radium Hospital is a public cancer research institution operating as part of Oslo University Hospital under the governance of the Southern and Eastern Norway Regional Health Authority (Helse Sør-Øst). Founded in 1954 and merged into Oslo University Hospital in 2009, its Institute for Cancer Research employs over 380 researchers across seven specialized departments: Cancer Genetics, Cancer Immunology, Molecular Cell Biology, Molecular Oncology, Radiation Biology, Tumor Biology, and Core Facilities. The institute conducts fundamental and translational cancer research with the goal of improving cancer diagnosis and treatment, including development of novel immunotherapies, cell therapies, and understanding of cancer cell survival mechanisms.

The institute's core technology portfolio includes an AI-Facilitated Immune Receptor Engineering (AFIRE) platform led by Johanna Olweus for developing soluble and cell-based immune receptors targeting intracellular proteins, iPSC-derived NK cell therapy for glioblastoma that overcomes resistance via B7-H3-targeted tri-specific killer engagers, and research on arginine deprivation therapy for ASS1-deficient cancers. These platforms combine laboratory research with AI-driven discovery approaches and are supported by an output of over 2,300 scientific articles annually from the broader Oslo University Hospital research community.

As a public research institution, The Norwegian Radium Hospital does not sell commercial products or services. Revenue mechanics rely on approximately 70% external grant funding from the Research Council of Norway, Helse Sør-Øst, international funding bodies, and the Norwegian Government/University of Oslo, with the balance from institutional allocations. Recent grants include 9 million NOK to Marina Vietri, 2 million NOK to Katarzyna Gajewska, and participation in a 25 million NOK (2026) / 50 million NOK annually (from 2027) emerging technologies initiative. Its primary beneficiaries are oncology patients served through Norway's public healthcare system; research outputs are disseminated via scientific publications, conference presentations, and technology transfer into clinical applications.

Name

The Norwegian Radium Hospital

Legal name

The Norwegian Radium Hospital

Website

https://radium.no

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

51–100 employees

Short description

The Norwegian Radium Hospital is a public cancer research institution within Oslo University Hospital, conducting fundamental and translational cancer research across seven specialized departments with 380+ researchers, primarily funded by Norwegian government grants to advance oncology treatments.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical Laboratories (621511)

SIC

Services-Hospitals (8060), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Radiation Oncology (HLAKAFAC), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), NK Cell Therapies (HLAAABAD), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Cancer research
• Translational oncology
• Cancer immunotherapy
• Radiation biology
• Molecular oncology

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grants and Funding: Public research institution primarily funded through competitive research grants from the Research Council of Norway (Norges Forskningsråd), regional health authorities (Helse Sør-Øst), and international funding bodies. Approximately 70% of employees and projects are externally funded through grant-based financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Norwegian Radium Hospital, operating through the Institute for Cancer Research at Oslo University Hospital, conducts fundamental and translational cancer research across seven specialized departments with more than 380 employees. The institute develops novel therapeutic strategies including AI-driven immune receptor engineering, iPSC-derived NK cell therapies for solid tumors, and arginine deprivation therapy, while translating laboratory discoveries into clinical applications for cancer patients.

Product overview

The Norwegian Radium Hospital, as part of Oslo University Hospital's Institute for Cancer Research, is a cancer research institution rather than a product company. The Institute operates as a research organization with seven research departments and over 380 employees conducting fundamental and translational cancer research. The institution does not offer commercial products or software services; its offerings consist of scientific research, publications, and research collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Research Services
• AI-Facilitated Immune Receptor Engineering (AFIRE)

Quantifiable outcome

• Over 2,300 scientific articles published annually
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Southern and Eastern Norway Regional Health AuthoritycoreStrategic or Co-development PartnerOslo University Hospital is part of Southern and Eastern Norway Regional Health Authority (Helse Sør-Øst), which provides institutional governance and funding for healthcare services and research activities.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Memorial Sloan Kettering Cancer Center: World-leading US cancer research and treatment center with extensive translational research programs. Comparable in cancer research focus and translational pipeline, though operating at much larger scale and with different funding mix.
• Institut Gustave Roussy: Leading European cancer research and treatment center in France, combining research with clinical oncology services. Comparable as a large-scale European public cancer research and hospital entity.
• Fred Hutchinson Cancer Center: Major US cancer research center with strong immunology, cell therapy, and translational research programs. Comparable for immunotherapy and cell therapy research programs (NK cell therapy, immune receptor engineering).
• German Cancer Research Center (DKFZ): Germany's largest biomedical research institute, focused on cancer with extensive government funding and broad research portfolio. Comparable as a publicly funded national cancer research center operating at significantly larger scale.

Direct peers

• Netherlands Cancer Institute (NKI): Dutch national cancer research and treatment center combining fundamental research with clinical applications. Direct peer as a European public cancer research institution with hybrid research-clinical delivery model.
• Karolinska Institutet: Sweden's premier medical research university with extensive cancer research programs across multiple departments. Directly comparable as a Scandinavian public research institution with similar funding model, multi-disciplinary structure, and translational oncology focus.
• Danish Cancer Society Research Center: National cancer research center in Denmark with similar structure to ICR—multi-departmental cancer research, government and charity funding, and translational focus. Direct peer in Scandinavian public cancer research.

Regional players

• University of Helsinki - Institute of Biotechnology: Nordic biomedical research institute with cancer research programs. Comparable as a Scandinavian public research institution with similar structure, though with broader life sciences focus beyond oncology.
• Lund University - Faculty of Medicine: Swedish medical faculty with strong cancer research and radiation biology programs. Comparable as a Scandinavian public academic research institution with overlapping oncology and radiation research focus.

Others

• European Organization for Research and Treatment of Cancer (EORTC): European intergovernmental research organization coordinating cancer clinical trials and translational research. Comparable as a peer institution in the European cancer research ecosystem with overlapping clinical-translational collaborations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutu.be/MtcgDwqB_6Q
• LinkedInlinkedin.com/company/the-norwegian-radium-hospital

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Norwegian Radium Hospital